Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018467 | 0.91 | CXCR4 (0.36) | CXCR4XIAPBIRC3BIRC2HDAC1 | |
| SCHEMBL6018341 | 0.87 | CXCR4 (0.38) | CXCR4HDAC1HDAC6RAB9ACYP3A4 | |
| SCHEMBL6018112 | 0.86 | HDAC1 (0.44) | CXCR4HDAC1HDAC6MCHR1ADORA2A | |
| SCHEMBL6018408 | 0.84 | HDAC1 (0.38) | CXCR4HDAC1HDAC6PSMB5MCHR1 | |
| SCHEMBL6018280 | 0.81 | CXCR4 (0.37) | CXCR4XIAPBIRC3BIRC2HDAC1 | |
| SCHEMBL6018611 | 0.81 | CXCR4 (0.44) | CXCR4HDAC1HDAC6ADORA2ACNR1 | |
| SCHEMBL6691032 | 0.80 | CXCR4 (0.36) | CXCR4HDAC1HDAC6CYP3A4ADORA2A | |
| SCHEMBL6019439 | 0.80 | SLC40A1 (0.36) | CXCR4HDAC1HDAC6MCHR1ADORA2A | |
| SCHEMBL6018194 | 0.80 | FNTA (0.38) | CXCR4HDAC1HDAC6ADORA2A | |
| SCHEMBL6018114 | 0.80 | CXCR4 (0.36) | CXCR4HDAC1HDAC6ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | CXCR4 2185/4885XIAP 1425/4885BIRC3 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.